BioSpace News Archive

Cold Genesys, Inc. today announced that it has entered into a clinical collaboration with Merck (known as MSD outside the United States and Canada) to evaluate the combination of Cold Genesys’ lead oncolytic immunotherapy candidate CG0070 with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), in a Phase 2 clinical study.

The December 13, 2018 webinar is open to hospital and health system personnel nationwide and will feature Dr. Richard E. Pratley of Florida Hospital System and Dr. Steven V. Edelman of UC San Diego Health.

Company’s New Guided Diuretic Therapy is in Development for the Optimization of Fluid Management for Patients with Heart Failure

Continuing to expand access to cancer care globally, Varian (NYSE: VAR) announced it was selected by Medical Specialist Holdings (MSH) to equip seven of its centers in South Africa with Varian linear accelerators and Eclipse™ treatment planning system.

Clinical Practice Guidelines Recognize Breast Cancer Index Clinical Utility Spans the Treatment Continuum for Patients with Early-Stage Estrogen Receptor Positive (ER+) Disease

Metastatic bone disease has proven to be more than agonizing for patients, especially when they discover that their cancer has reached an advanced stage, thereby diminishing their chance of survival and adding to the treatment costs.

This study compares standard of care to SOC plus BIO-11006 in 60 patients with stage 4, NSCLC.

The Discovery/Vitality study by RAND Europe demonstrates how incentives in the Vitality Shared-Value Insurance model combined with Apple Watch deliver dramatic and sustained improvements in physical activity levels.

Investors welcome VALBIOTIS’ initial public offering in 2017

The patent covers first-in-class novel hematopoietic stem cell technology for targeted immunotherapies in hematologic malignancies